Register entry
- Registered sites
- 0
- Active NDC listings
- 6
- Live patents
- 448
- Exclusivities
- 1
- Countries
- 0
Catalogue
Drug listings by form and route
66 active NDC listings: 6 human prescription drug. By marketing category: NDA 6.
| Dosage form | NDCs |
|---|---|
| tablet, film coated | 3 |
| capsule | 2 |
| suspension | 1 |
| Route | NDCs |
|---|---|
| oral | 6 |
| Labeller name on the listing | NDCs |
|---|---|
| pharmacyclics llc | 6 |
Exclusivity
Patents and exclusivities
448| Patent | Product | Covers | Expiry |
|---|---|---|---|
| 7514444 | IMBRUVICAibrutinib | substance, product | Dec 2026 |
| 8476284 | IMBRUVICAibrutinib | use | Dec 2026 |
| 8497277 | IMBRUVICAibrutinib | use | Dec 2026 |
| 8697711 | IMBRUVICAibrutinib | substance, product | Dec 2026 |
| 8703780 | IMBRUVICAibrutinib | use | Dec 2026 |
| 8735403 | IMBRUVICAibrutinib | substance, product | Dec 2026 |
| 8754091 | IMBRUVICAibrutinib | product | Dec 2026 |
| 8952015 | IMBRUVICAibrutinib | use | Dec 2026 |
| 8957079 | IMBRUVICAibrutinib | substance, product | Dec 2026 |
| 9181257 | IMBRUVICAibrutinib | substance, product | Dec 2026 |
| 8563563 | IMBRUVICAibrutinib | use | Apr 2027 |
| 7514444*PED | IMBRUVICAibrutinib | use | Jun 2027 |
| 8476284*PED | IMBRUVICAibrutinib | use | Jun 2027 |
| 8497277*PED | IMBRUVICAibrutinib | use | Jun 2027 |
| 8697711*PED | IMBRUVICAibrutinib | use | Jun 2027 |
| 8703780*PED | IMBRUVICAibrutinib | use | Jun 2027 |
| 8735403*PED | IMBRUVICAibrutinib | use | Jun 2027 |
| 8754091*PED | IMBRUVICAibrutinib | use | Jun 2027 |
| 8952015*PED | IMBRUVICAibrutinib | use | Jun 2027 |
| 8957079*PED | IMBRUVICAibrutinib | use | Jun 2027 |
| 9181257*PED | IMBRUVICAibrutinib | use | Jun 2027 |
| 8563563*PED | IMBRUVICAibrutinib | use | Oct 2027 |
| 8008309 | IMBRUVICAibrutinib | substance, product | Nov 2027 |
| 8008309*PED | IMBRUVICAibrutinib | use | May 2028 |
| 10004746 | IMBRUVICAibrutinib | use | Jun 2031 |
| 10016435 | IMBRUVICAibrutinib | use | Jun 2031 |
| 10478439 | IMBRUVICAibrutinib | use | Jun 2031 |
| 10653696 | IMBRUVICAibrutinib | use | Jun 2031 |
| 10751342 | IMBRUVICAibrutinib | use | Jun 2031 |
| 11672803 | IMBRUVICAibrutinib | use | Jun 2031 |
| 8754090 | IMBRUVICAibrutinib | use | Jun 2031 |
| 8999999 | IMBRUVICAibrutinib | use | Jun 2031 |
| 9125889 | IMBRUVICAibrutinib | use | Jun 2031 |
| 9801881 | IMBRUVICAibrutinib | use | Jun 2031 |
| 9801883 | IMBRUVICAibrutinib | use | Jun 2031 |
| 9814721 | IMBRUVICAibrutinib | use | Jun 2031 |
| 10004746*PED | IMBRUVICAibrutinib | use | Dec 2031 |
| 10016435*PED | IMBRUVICAibrutinib | use | Dec 2031 |
| 10478439*PED | IMBRUVICAibrutinib | use | Dec 2031 |
| 10653696*PED | IMBRUVICAibrutinib | use | Dec 2031 |
| 10751342*PED | IMBRUVICAibrutinib | use | Dec 2031 |
| 8754090*PED | IMBRUVICAibrutinib | use | Dec 2031 |
| 8999999*PED | IMBRUVICAibrutinib | use | Dec 2031 |
| 9125889*PED | IMBRUVICAibrutinib | use | Dec 2031 |
| 9801881*PED | IMBRUVICAibrutinib | use | Dec 2031 |
| 9801883*PED | IMBRUVICAibrutinib | use | Dec 2031 |
| 9814721*PED | IMBRUVICAibrutinib | use | Dec 2031 |
| 10106548 | IMBRUVICAibrutinib | substance, product | Jun 2033 |
| 10125140 | IMBRUVICAibrutinib | substance, product | Jun 2033 |
| 10294231 | IMBRUVICAibrutinib | product | Jun 2033 |
| 10294232 | IMBRUVICAibrutinib | product | Jun 2033 |
| 10752634 | IMBRUVICAibrutinib | product | Jun 2033 |
| 10961251 | IMBRUVICAibrutinib | product | Jun 2033 |
| 9713617 | IMBRUVICAibrutinib | product | Jun 2033 |
| 9725455 | IMBRUVICAibrutinib | substance | Jun 2033 |
| 9540382 | IMBRUVICAibrutinib | use | Aug 2033 |
| 9296753 | IMBRUVICAibrutinib | substance, product | Oct 2033 |
| 10106548*PED | IMBRUVICAibrutinib | use | Dec 2033 |
| 10125140*PED | IMBRUVICAibrutinib | use | Dec 2033 |
| 10294231*PED | IMBRUVICAibrutinib | use | Dec 2033 |
| Product | Exclusivity | Until |
|---|---|---|
| IMBRUVICAIBRUTINIB | PED Paediatric | Feb 2030 |
Catalogue
Marketed products
6| Brand | Generic name | Form / route | NDC |
|---|---|---|---|
| Imbruvica | Ibrutinib | suspension, oral | 57962-007NDA |
| Imbruvica | Ibrutinib | tablet, film coated, oral | 57962-014NDA |
| Imbruvica | Ibrutinib | capsule, oral | 57962-070NDA |
| Imbruvica | Ibrutinib | capsule, oral | 57962-140NDA |
| Imbruvica | Ibrutinib | tablet, film coated, oral | 57962-280NDA |
| Imbruvica | Ibrutinib | tablet, film coated, oral | 57962-420NDA |
Compare
Other companies listing ibrutinib
- Catalent Pharma Solutions Inc.22 sites · 261 NDC
- Dr. Reddy's Laboratories Limited15 sites · 683 NDC
- AbbVie Inc.13 sites · 131 NDC
- Hetero Labs Limited8 sites · 167 NDC
- AARTI PHARMALABS LIMITED3 sites · 34 NDC
- SHILPA PHARMA LIFESCIENCES LIMITED2 sites · 40 NDC
- ScinoPharm Taiwan, Ltd.1 site · 87 NDC
- Zhejiang Ausun Pharmaceutical Co., Ltd.1 site · 55 NDC
- Dr. Reddys Laboratories Limited0 sites · 220 NDC
Enquiry
Common questions
- Is Pharmacyclics LLC FDA approved?
- Pharmacyclics LLC holds no registered establishment of its own; 6 drug products are listed under its name in the National Drug Code Directory, made at sites registered to other firms.
- What drugs does Pharmacyclics LLC make?
- 6 products are listed under Pharmacyclics LLC in the openFDA NDC Directory, most often as tablet, film coated; capsule; suspension. The full breakdown by dosage form and route is above. A listing count is not a sales figure.
Compiled from FDA establishment registrations, the openFDA NDC Directory, the Orange Book and the FDA drug shortage database. Not claimed by the company. Sources and methodology.